RLAY
Relay Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$19.18-3.67%
Price as of Jul 20, 2026
RLAY financials
Relay Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $15.4M | $10.0M | $25.5M | $1.4M |
| Cost of revenue | $3.6M | $315.4M | $326.4M | $243.0M |
| Gross profit | $11.8M | -$305.4M | -$300.8M | -$241.6M |
| Operating expenses | $314.5M | $67.0M | $72.2M | $57.7M |
| Operating income | -$302.7M | -$372.5M | -$373.0M | -$299.3M |
| Net income | -$276.5M | -$337.7M | -$342.0M | -$290.5M |
| EBITDA | -$272.9M | -$380.2M | -$374.2M | -$306.8M |
| Basic EPS | $-1.61 | $-2.36 | $-2.79 | $-2.59 |
| Diluted EPS | $-1.61 | $-2.36 | $-2.79 | $-2.59 |
| Balance sheet | ||||
| Cash & equivalents | $84.0M | $124.3M | $143.7M | $151.8M |
| Total assets | $621.3M | $871.3M | $844.0M | $1.1B |
| Total liabilities | $54.3M | $93.5M | $92.0M | $149.6M |
| Stockholders’ equity | $567.1M | $777.8M | $752.0M | $950.2M |
| Total debt | $32.5M | $48.5M | $53.5M | $57.7M |
| Net debt | -$51.6M | -$75.8M | -$90.3M | -$94.1M |
| Cash flow | ||||
| Operating cash flow | -$235.5M | -$249.1M | -$300.3M | -$229.5M |
| Capital expenditure | -$410.0K | -$2.0M | -$4.1M | -$9.1M |
| Free cash flow | -$235.9M | -$251.1M | -$304.4M | -$238.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |